Tags

Type your tag names separated by a space and hit enter

High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation.
Bone Marrow Transplant. 2004 May; 33(9):931-5.BM

Abstract

Cytomegalovirus (CMV) disease remains an important cause of morbidity and mortality in patients undergoing hematopoietic stem cell transplantation (HSCT). We evaluated high-dose acyclovir (HDACV) and pre-emptive ganciclovir to prevent CMV disease in 76 children who underwent peripheral blood stem cell transplantation (PBSCT) and were at risk for CMV reactivation and disease (both recipient and donor seropositive) from May 1998 to April 2003. All received HDACV from day -9 to 6 months post transplant in conjunction with weekly CMV pp65 antigenemia monitoring. The incidence of antigenemia in this cohort was 19.7%, at a median of 22 days post-PBSCT. The frequencies were 26.4 and 4.4% in allogeneic and autologous groups, respectively (P=0.03). Patients with nonmalignant disease had higher CMV antigenemia than those with malignant disease (30.8 vs 8.1%, P=0.02). Age at PBSCT, sex, graft-versus-host disease (GVHD) prophylaxis regimen and presence of acute GVHD did not affect the risk of CMV antigenemia. None of the patients who had positive pp65 antigenemia developed CMV disease during the study period. We conclude that pp65 antigenemia-guided HDACV and pre-emptive ganciclovir may prevent CMV disease in children undergoing PBSCT.

Authors+Show Affiliations

Department of Pediatric Hematology & Oncology, Akdeniz University Medical Faculty, Antalya, Turkey. volkan_hazar@yahoo.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15034541

Citation

Hazar, V, et al. "High-dose Acyclovir and Pre-emptive Ganciclovir in Prevention of Cytomegalovirus Disease in Pediatric Patients Following Peripheral Blood Stem Cell Transplantation." Bone Marrow Transplantation, vol. 33, no. 9, 2004, pp. 931-5.
Hazar V, Kansoy S, Küpesiz A, et al. High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation. Bone Marrow Transplant. 2004;33(9):931-5.
Hazar, V., Kansoy, S., Küpesiz, A., Aksoylar, S., Kantar, M., & Yeşilipek, A. (2004). High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation. Bone Marrow Transplantation, 33(9), 931-5.
Hazar V, et al. High-dose Acyclovir and Pre-emptive Ganciclovir in Prevention of Cytomegalovirus Disease in Pediatric Patients Following Peripheral Blood Stem Cell Transplantation. Bone Marrow Transplant. 2004;33(9):931-5. PubMed PMID: 15034541.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation. AU - Hazar,V, AU - Kansoy,S, AU - Küpesiz,A, AU - Aksoylar,S, AU - Kantar,M, AU - Yeşilipek,A, PY - 2004/3/23/pubmed PY - 2004/12/16/medline PY - 2004/3/23/entrez SP - 931 EP - 5 JF - Bone marrow transplantation JO - Bone Marrow Transplant VL - 33 IS - 9 N2 - Cytomegalovirus (CMV) disease remains an important cause of morbidity and mortality in patients undergoing hematopoietic stem cell transplantation (HSCT). We evaluated high-dose acyclovir (HDACV) and pre-emptive ganciclovir to prevent CMV disease in 76 children who underwent peripheral blood stem cell transplantation (PBSCT) and were at risk for CMV reactivation and disease (both recipient and donor seropositive) from May 1998 to April 2003. All received HDACV from day -9 to 6 months post transplant in conjunction with weekly CMV pp65 antigenemia monitoring. The incidence of antigenemia in this cohort was 19.7%, at a median of 22 days post-PBSCT. The frequencies were 26.4 and 4.4% in allogeneic and autologous groups, respectively (P=0.03). Patients with nonmalignant disease had higher CMV antigenemia than those with malignant disease (30.8 vs 8.1%, P=0.02). Age at PBSCT, sex, graft-versus-host disease (GVHD) prophylaxis regimen and presence of acute GVHD did not affect the risk of CMV antigenemia. None of the patients who had positive pp65 antigenemia developed CMV disease during the study period. We conclude that pp65 antigenemia-guided HDACV and pre-emptive ganciclovir may prevent CMV disease in children undergoing PBSCT. SN - 0268-3369 UR - https://www.unboundmedicine.com/medline/citation/15034541/High_dose_acyclovir_and_pre_emptive_ganciclovir_in_prevention_of_cytomegalovirus_disease_in_pediatric_patients_following_peripheral_blood_stem_cell_transplantation_ L2 - https://doi.org/10.1038/sj.bmt.1704463 DB - PRIME DP - Unbound Medicine ER -